Beneficial cilostazol therapeutic effects in mdx dystrophic skeletal muscle

Autor(es)

Hermes, Tulio de Almeida ; Macedo, Aline Barbosa ; Fogaca, Aline Reis ; Rapucci Moraes, Luis Henrique ; de Faria, Felipe Meira ; Kido, Larissa Akemi ; Alves Cagnon, Valeria Helena ; Minatel, Elaine

• Tipo de documento: Artigo Científico
• Fonte: Clinical and experimental pharmacology & physiology; v. 43, n. 2, p. 9-pg., 2016-02-01.

Resumo

This study evaluated the possible protective effects of cilostazol against myonecrosis in dystrophic diaphragm muscle invivo, focusing on oxidative stress, the inflammatory response and angiogenesis. Young mdx mice, the experimental animal for Duchenne muscular dystrophy, received cilostazol for 14days. A second group of mdx mice and a control group of C57BL/10 mice received a saline solution. In the mdx mice, cilostazol treatment was associated with reduced loss of muscle strength (-34.4%), decreased myonecrosis, reduced creatine kinase levels (-63.3%) and muscle fibres stained for immunoglobulin G in dystrophic diaphragm muscle (-81.1%), and a reduced inflammatory response, with a decreased inflammatory area (-22%), macrophage infiltration (-44.9%) and nuclear factor-B (-24%) and tumour necrosis factor- (-48%) content in dystrophic diaphragm muscle. Furthermore, cilostazol decreased oxidative stress and attenuated reactive oxygen species production (-74%) and lipid peroxidation (-17%) in dystrophic diaphragm muscle, and promoted the up-regulation of angiogenesis, increasing the number of microvessels (15%). In conclusion, the present results show that cilostazol has beneficial effects in dystrophic muscle. More research into the potential of cilostazol as a novel therapeutic agent for the treatment of dystrophinopathies is required. (AU)

• Processo FAPESP: 11/02474-4 - Tratamento in vivo e in vitro com bloqueador de cálcio e antioxidante em camundongos mdx
• Beneficiário: Elaine Minatel
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/17299-9 - Efeito da associação de anti-inflamatório e antioxidante sobre células musculares distróficas
• Beneficiário: Aline Reis Fogaça
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 13/01294-8 - A controvertida relação entre lesões prostáticas e inflamação: tratamentos com Celecoxibe e Goniotalamina em camundongos senis (FVB) e portadores do gene para o adenocarcinoma prostático (TRAMP)
• Beneficiário: Larissa Akemi Kido de Barros
• Modalidade de apoio: Bolsas no Brasil - Doutorado